Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide.

[1]  K. Flaherty,et al.  Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. , 2008, The Journal of investigative dermatology.

[2]  P. Valent,et al.  Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. , 2007, The Journal of investigative dermatology.

[3]  H. Bojar,et al.  ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. , 2007, The Journal of investigative dermatology.

[4]  P. Hersey,et al.  Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1 , 2007, Clinical Cancer Research.

[5]  M. Soengas,et al.  Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins , 2007, Cell Death and Differentiation.

[6]  C. Garbe,et al.  Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment , 2007, The British journal of dermatology.

[7]  M. Zvelebil,et al.  Exploring the specificity of the PI3K family inhibitor LY294002. , 2007, The Biochemical journal.

[8]  R. Scolyer,et al.  Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma , 2007, Modern Pathology.

[9]  P. Valent,et al.  CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model , 2007, Pharmacology.

[10]  L. Weber,et al.  In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway– and microtubule-targeting inhibitors , 2007, Molecular Cancer Therapeutics.

[11]  V. Sondak,et al.  Chemotherapy for metastatic melanoma , 2007, Cancer.

[12]  James T. Elder,et al.  A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. , 2006, Cancer research.

[13]  S. Winograd-Katz,et al.  Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor , 2006, Oncogene.

[14]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[15]  Kazuhiro Takahashi,et al.  Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. , 2006, Endocrinology.

[16]  K. Flaherty.  Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma , 2006, Clinical Cancer Research.

[17]  Hong Zhang,et al.  Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis. , 2006, International journal of oncology.

[18]  P. Hersey.  Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma , 2006, Current opinion in oncology.

[19]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[20]  R. Stahel,et al.  Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation , 2005, International journal of cancer.

[21]  J. Gills,et al.  Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. , 2005, Cancer research.

[22]  Gang Li,et al.  The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. , 2005, Frontiers in bioscience : a journal and virtual library.

[23]  Gerolama Condorelli,et al.  PED mediates AKT-dependent chemoresistance in human breast cancer cells. , 2005, Cancer research.

[24]  T. Kwon,et al.  LY294002 inhibits LPS-induced NO production through a inhibition of NF-kappaB activation: independent mechanism of phosphatidylinositol 3-kinase. , 2005, Immunology letters.

[25]  Mustafa Al-Chalabi,et al.  LY-294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] Affects Calcium Signaling in Airway Smooth Muscle Cells Independently of Phosphoinositide 3-Kinase Inhibition , 2004, Journal of Pharmacology and Experimental Therapeutics.

[26]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[27]  C. Marshall,et al.  B-RAF is a therapeutic target in melanoma , 2004, Oncogene.

[28]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[29]  H. Pehamberger,et al.  Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. , 2003, The Journal of investigative dermatology.

[30]  R. Offringa,et al.  Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. , 2003, Blood.

[31]  J. Litz,et al.  Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. , 2002, Molecular cancer therapeutics.

[32]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[33]  Walter Kolch,et al.  Ras/Raf signalling and emerging pharmacotherapeutic targets , 2002, Expert opinion on pharmacotherapy.

[34]  R. Craig.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis , 2002, Leukemia.

[35]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[36]  R. Tallarida.  Response Surface Analysis of Drug Combinations , 2000 .

[37]  Min-Liang Kuo,et al.  The Antiapoptotic Gene mcl-1 Is Up-Regulated by the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway through a Transcription Factor Complex Containing CREB , 1999, Molecular and Cellular Biology.

[38]  C. Garbe,et al.  A fluorometric rapid microassay to identify anti‐proliferative compounds for human melanoma cells in vitro , 1991, Melanoma research.

[39]  M. Pittelkow,et al.  New techniques for the in vitro culture of human skin keratinocytes and perspectives on their use for grafting of patients with extensive burns. , 1986, Mayo Clinic proceedings.

[40]  Gang Li,et al.  The role of Bcl-2 family members in the progression of cutaneous melanoma , 2004, Clinical & Experimental Metastasis.

[41]  D. Grossman,et al.  Apoptosis regulators and responses in human melanocytic and keratinocytic cells. , 2003, The Journal of investigative dermatology.

[42]  D. Elder,et al.  Human melanoma progression in skin reconstructs : biological significance of bFGF. , 2000, The American journal of pathology.